Alere Determine Combo HIV 1/2 Ag/Ab rapid test for HIV
Alere Australia has gained approval for the marketing in Australia of the Alere Determine Combo HIV 1/2 Ag/Ab rapid test for HIV. This marks the first approval for an innovative HIV assay to be included on the Australian Register of Therapeutic Goods (ARTG) for use in a point-of-care situation.
Marketing approval required lengthy scrutiny by the TGA of the scientific and clinical evidence supporting the test, including its accuracy when performed in near patient situations by healthcare professionals other than pathology laboratory scientists.
The point-of-care test offers significant benefits to patients and to healthcare workers in terms of convenience and rapid management of immediate clinical issues. It brings HIV testing technology right to the patient’s bedside.
Phone: 07 3363 7100
Beckman Coulter Life Sciences Basophil Activation Test (BAT) for food allergy research
Beckman Coulter Life Sciences introduces its next-generation Basophil Activation Test (BAT) to...
TopoGEN Topoisomerase Assay Kits
TopoGEN provides innovative reagents and kits for topoisomerase research and mechanism-based drug...
Alamar Biosciences NULISAseq Mouse Panel 120 for protein biomarker analysis
The multiplex panel encompasses a wide selection of proteins essential for studying key...
